Results
6Johnson & Johnson reports Q3 2026 results, raises 2026 guidanceGuidance raised
52026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*
2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals
Outlook
1Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpointGuidance raised
Corporate events
4Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer
Management commentary
“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer.
“In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma.
This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”
Results
Regional sales results
Segment sales results
Management commentary
Third-Quarter 2026 segment commentary:
Innovative Medicine
Results
7Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points.
Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience.
3Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology.
Management commentary
MedTech
Results
8MedTech worldwide operational sales grew 2.5%*.
Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics.
Outlook
Full-year 2026 guidance:
($ in Billions, except EPS)October 2026July 29, 2026
Adjusted Operational Sales 1,2 Change vs. Prior Year / Mid-point6.4% – 6.8% / 6.6%6.2% – 6.8% / 6.5%
Operational Sales 2 / Mid-point Change vs. Prior Year / Mid-point$100.5B – $100.9B /$100.7B 6.7% – 7.1% / 6.9%$100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8%
Estimated Reported Sales 3 / Mid-point Change vs. Prior Year / Mid-point$101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4%$100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3%
Adjusted Operational EPS (Diluted) 2,4 / Mid-point Change vs. Prior Year / Mid-point$10.95 – $11.05 / $11.00 1.5% – 2.4% / 2.0%$10.86 – $11.01 / $10.94 0.7% – 2.1% / 1.4%
Adjusted EPS (Diluted) 3,4 / Mid-point Change vs. Prior Year / Mid-point$11.05 – $11.15 / $11.10 2.4% – 3.3% / 2.9%$10.96 – $11.11 / $11.04 1.6% – 3.0% / 2.3%
3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only)
Corporate events
Notable announcements in the quarter:
RegulatoryJohnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses 1Press Release
2FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patientsPress Release
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerPress Release
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical SystemPress Release
Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted BronchoscopyPress Release
1 Subsequent to the quarter
57 boilerplate lines (safe-harbor disclaimer, contacts, call details) are set aside.